- Partnering of
- Phase 1 APN01 to
- €207,000,000
Deal Landscape
- Apeiron Biologics is a biotech company with a focus on biological and immunological approaches to treating life-threatening diseases
- The Company has a broad product portfolio of late- and mid-stage development candidates. One of these products is APN01, a recombinant human Angiotensin Converting Enzyme 2 (rhACE2) therapeutic that was in Phase I development for the treatment of Acute Respiratory Distress Syndrome (ARDS)
JSB’s Role
- Apeiron selected JSB to aid in the identification and selection of a partner for APN01
- JSB orchestrated a competitive auction process in order to drive competition for the product
- GlaxoSmithKline (NYSE:GSK) emerged as the leading potential partner for the development asset
Successful Close
- JSB’s efforts ultimately resulted in a licensing agreement with GSK for £11 million in upfront cash and equity investments, plus milestone payments that could reach £207. million . The agreement also includes royalties on future net sales
- GSK has initiated a Phase IIa study of APN01 in Acute Lung Injury and development work continues to progress